Singular Genomics Systems (OMIC – Research Report) received a Hold rating and price target from J.P. Morgan analyst Julia Qin yesterday. The company’s shares closed yesterday at $4.31.
Qin covers the Healthcare sector, focusing on stocks such as Invitae, 10x Genomics, and Seer. According to TipRanks, Qin has an average return of 19.3% and a 75.00% success rate on recommended stocks.
In addition to J.P. Morgan, Singular Genomics Systems also received a Hold from Goldman Sachs’s Matthew Sykes in a report issued on August 10. However, on the same day, Bank of America Securities downgraded Singular Genomics Systems (NASDAQ: OMIC) to a Sell.
See Insiders’ Hot Stocks on TipRanks >>
OMIC market cap is currently $304.2M and has a P/E ratio of -3.70.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OMIC in relation to earlier this year. Last month, David L. Barker, a Director at OMIC bought 60,000.00 shares for a total of $37,800.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Integrated Solution is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Read More on OMIC:
- J.P. Morgan downgrades Invitae (NVTA) to a Sell
- J.P. Morgan Sticks to Its Hold Rating for Charter Hall Social Infrastructure REIT (FKKEF)
- Analysts Have Conflicting Sentiments on These Financial Companies: Alexandria Equities (ARE), Regency Centers (REG) and ASX Limited (OtherASXFF)
- GPT Group (GPTGF) Gets a Sell from J.P. Morgan
- J.P. Morgan Reaffirms Their Buy Rating on Insurance Australia Group Limited (IAUGF)
